While the benefits of screening tests for cervical cancer, breast cancer, and colorectal cancer are widely accepted, screening for prostate cancer remains controversial to some. The main screening ...

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stock offering that could add ...